LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid POC Antigen and Molecular COVID-19 Tests May Not Be Accurate Enough to Replace RT-PCR Tests, Finds Study

By LabMedica International staff writers
Posted on 31 Aug 2020
Illustration
Illustration
A new study has revealed that rapid point-of-care antigen and molecular tests may not be accurate enough to replace RT-PCR for diagnosing COVID-19 infection.

Researchers from Cochrane (London, UK), a global independent organization that reviews evidence from research to inform health decision-making, looked for studies that measured the accuracy of rapid point-of-care tests compared with RT-PCR tests to detect current COVID-19 infection. They found 18 relevant studies, out of which 10 studies has taken place in North America, four in Europe, two in South America, one in China and one in multiple countries. Nine studies deliberately included a high percentage of people with confirmed COVID-19 or included only people with COVID-19, while 14 studies did not provide any information about the people providing the samples for testing and 12 studies did not provide any information about where people were tested. None of the studies reported included samples from people without symptoms.

The researchers found that five studies reported eight evaluations of five different antigen tests. Overall, there was considerable variation between the results of the antigen tests in how well they detected COVID-19 infection. Tests gave false positive results in less than 1% of samples. They also found that 13 evaluations of four different molecular tests correctly detected an average of 95% of samples with COVID-19 infection. Around 1% of samples gave false positive results. The team noted a large difference in COVID-19 detection between the two most commonly evaluated molecular tests.

The researchers believe that the findings currently have limited applicability, as they are uncertain whether tests will perform in the same way in clinical practice, and according to symptoms of COVID‐19, duration of symptoms, or in asymptomatic people. Rapid tests have the potential to be used to inform triage of RT‐PCR use, allowing earlier detection of those testing positive, although the evidence currently is not strong enough to determine how useful they are in clinical practice, according to the researchers.

Related Links:
Cochrane

Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Alcohol Testing Device
Dräger Alcotest 7000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more